ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2019
Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.
Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01885208. Cited by 11 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3 - vs. QW GLP-1)
Who cites it
11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering Medications in Treating Type 2 Diabetes: A Comprehensive Systematic Review and Meta-analysis.Diabetes care · 2025Pooled it
- A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus.PharmacoEconomics · 2023Pooled it
- Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs.BMC endocrine disorders · 2022 · on this mapPooled it
- Cost-Consequence Analysis of Semaglutide vs. Liraglutide for Managing Obese Prediabetic and Diabetic Patients in Saudi Arabia: A Single-Center Study.Healthcare (Basel, Switzerland) · 2025Article
- Metabolic interventions as adjunctive therapies to insulin in type 1 diabetes: Current clinical landscape and perspectives.Diabetes, obesity & metabolism · 2025Review
- Framework for developing cost-effectiveness analysis threshold: the case of Egypt.The Journal of the Egyptian Public Health Association · 2024Article
- Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Article
- Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11.Diabetes, obesity & metabolism · 2023Article
- The burden of poor glycaemic control in people with newly diagnosed type 2 diabetes in Sweden: A health economic modelling analysis based on nationwide data.Diabetes, obesity & metabolism · 2021Article
- Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020Article
- Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.BMJ open diabetes research & care · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOnce-weekly semaglutide is a novel glucagon-like peptide-1 (GLP-1) analogue for the treatment of type 2 diabetes that was associated with greater reductions in glycated hemoglobin (HbA1c) and body mass index (BMI) versus once-daily GLP-1 analogue liraglutide in a recent network meta-analysis (NMA). The aim of the present study was to assess the long-term cost-effectiveness of once-weekly semaglutide 1 mg versus liraglutide 1.2 mg in Estonia.
methodsOutcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model (version 9.0), with baseline cohort characteristics sourced from SUSTAIN 3 and changes in HbA1c, systolic blood pressure (SBP), and BMI associated with once-weekly semaglutide and liraglutide derived from the NMA. Patients were assumed to receive once-weekly semaglutide or liraglutide for 5 years before intensifying to basal insulin. Treatment effects were applied for the first 5 years, after which HbA1c increased to 7.0%, SBP followed a natural progression, and BMI reverted to baseline for the remainder of the analysis. Costs were expressed in euros (EUR) and estimated from a healthcare payer perspective. Utilities associated with diabetes and diabetes-related complications were taken from published sources.
resultsOnce-weekly semaglutide 1 mg was associated with improvements in quality-adjusted life expectancy of 0.13 quality-adjusted life years (QALYs) versus liraglutide 1.2 mg. Direct costs were EUR 67 higher with once-weekly semaglutide, due to the increased acquisition cost, but this was mostly offset by cost savings due to avoidance of diabetes-related complications. Once-weekly semaglutide 1 mg was therefore associated with an incremental cost-effectiveness ratio of EUR 523 per QALY gained versus liraglutide 1.2 mg, which falls well below a willingness-to-pay threshold of EUR 52,390 per QALY gained (three times the Estonian GDP per capita).
conclusionOnce-weekly semaglutide was considered highly cost-effective versus liraglutide 1.2 mg for the treatment of patients with type 2 diabetes in Estonia.
fundingNovo Nordisk A/S. Plain language summary available for this article.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.